Medical Technology and Innovations, Inc. Announces United States Patent Office Issues Notice of Allowance for the Utility Patent on Female Incontinence Control Device.

Business Editors/Health & Medical Writers

LANCASTER, Pa.--(BW HealthWire)--June 18, 2002

Company Plans Worldwide Launch of Its Steridyne IVD Shortly

Medical Technology & Innovations, Inc. (MTI) (OTCBB:MTIV.OB-NEWS), the company known for innovative medical devices and products, announced today that it has received notice of allowance from the United States Patent Office for the Utility Patent which was issued June 12, 2002 for the Female Incontinence Control Device.

Mr. Jeremy P. Feakins, Chairman and Chief Executive Officer said, "We are thrilled that we have received notice of allowance from the United States Patent Office for the utility patent on our new female incontinence control device, Steridyne IVD. This notice, together with recent FDA clearance for Steridyne IVD places us closer toward our worldwide launch of the device."

Mr. Larry James, PA, Senior Vice President of Medical Affairs and R&D commented, "Receiving this notice provides us with the necessary proprietary technology protection for the incontinence control device. Steridyne IVD is a world-class device that promises relief to millions of women worldwide who suffer from female urinary incontinence. In the USA alone, more than 12 million women suffer from incontinence. Our new-patented device, Steridyne IVD(TM) will offer to these women a control device that offers a simple, hygienic and non-surgical solution. Urinary incontinence is a costly condition for patients because of the use of absorbent products, laundry costs, urinary tract and skin infections, and pharmaco-therapy. Supplementary costs, which are more difficult to quantify, include caregiver time, patient social stigma and hygienic problems associated with UI." Mr. James also stated the overall economic burden of urinary incontinence is extremely high ($17.5 Billion annually) as shown by a cost comparison analysis of 9 prevalent diseases.

                            COST OF ILLNESS
--------------------------------------------- ------------------------
                  DISEASE                                COST
--------------------------------------------- ------------------------
               Breast Cancer                             8.9
--------------------------------------------- ------------------------
            Pneumonia/Influenza                          15.8
--------------------------------------------- ------------------------
                Incontinence                             17.5
--------------------------------------------- ------------------------
                 Arthritis                               17.6
--------------------------------------------- ------------------------
                   Stroke                                25.5
--------------------------------------------- ------------------------
            Dementia/Alzheimer's                         25.8
--------------------------------------------- ------------------------
                  Smoking                                27.0
--------------------------------------------- ------------------------
                  Diabetes                               41.4
--------------------------------------------- ------------------------
                    CHD                                  46.0
--------------------------------------------- ------------------------

MTI recently reported on the 100% successful outcome of medical trials conducted by Dr. Felecia Froe, Director, UroCare for Women, LLC based in Kansas City, MO. Dr. Froe, one of only seventy-five female urologists in the USA, reported: "The Urinary Incontinence Device developed by Medical Technology and Innovations, shows tremendous promise as a solution for women with incontinence. The device will be a much needed solution for women everywhere who suffer from this problem."

About MTI

MTI is a growth stage company that has developed proven technology. MTI has developed Steridyne IVD(TM), a patented female urinary incontinence control device. Steridyne IVD has completed pre-market testing and will be launched shortly. Steridyne Corporation, a wholly owned subsidiary of MTI, is a developer, manufacturer and importer of a wide range of health care products to the consumer, professional and ethical markets. MTI is also the developer and manufacturer of the PhotoScreener(TM), a patented first-to-market device that can screen preverbal, special needs children and others for signs of serious eye conditions before irreversible problems occur.

Note: This News Release contains certain "forward-looking statements" as such term is defined in the Private Securities Litigation Reform Act of 1995 and information relating to the Company are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management.

Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, the interest rate environment, governmental regulation and supervision, seasonality, distribution networks product introductions and acceptance, technological change, changes in industry practices, and one-time events.

Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein.

For more information, please contact:

Product/Technical Inquiries: Larry James, PA Senior Vice President of Medical Affairs 816/525-6677

Investor Inquiries: Dennis Surovcik, SVP and Chief Financial Officer: 717/393-8000 http://www.mticompanies.com